Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $5.4 million.

  • Protalix BioTherapeutics' Accounts Payables fell 7254.43% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year decrease of 7254.43%. This contributed to the annual value of $4.5 million for FY2024, which is 493.06% up from last year.
  • Protalix BioTherapeutics' Accounts Payables amounted to $5.4 million in Q3 2025, which was down 7254.43% from $6.7 million recorded in Q2 2025.
  • Over the past 5 years, Protalix BioTherapeutics' Accounts Payables peaked at $19.6 million during Q3 2024, and registered a low of $4.1 million during Q1 2025.
  • Over the past 5 years, Protalix BioTherapeutics' median Accounts Payables value was $14.4 million (recorded in 2022), while the average stood at $13.0 million.
  • As far as peak fluctuations go, Protalix BioTherapeutics' Accounts Payables skyrocketed by 4645.03% in 2023, and later tumbled by 7804.48% in 2025.
  • Protalix BioTherapeutics' Accounts Payables (Quarter) stood at $16.4 million in 2021, then fell by 25.33% to $12.3 million in 2022, then plummeted by 64.8% to $4.3 million in 2023, then grew by 4.93% to $4.5 million in 2024, then grew by 18.57% to $5.4 million in 2025.
  • Its Accounts Payables was $5.4 million in Q3 2025, compared to $6.7 million in Q2 2025 and $4.1 million in Q1 2025.